NCT02970279

Brief Summary

Depression is one of the most common mental health disorders and it is estimated up to 50% of patients do not respond to evidenced-based psychotherapy treatment, recording a 'stasis' outcome. However, there is limited research understanding this population, meaning a considerable number of people continue to suffer. The purpose of this study is to 1) identify depression stasis prevalence and predictors in an existing evidenced-based group treatment for depression, 2) run a clinical trial to test whether an embedded intervention based on theoretical and clinical practice evidence can help reduce patient depression stasis and drop-out rates and 3) understand what aspect of therapy produces change (or prevents change in stasis). The study will be based on behavioural activation (BA) therapy delivered in an eight-session group format in an Improving Access to Psychological Therapies (IAPT) service in the United Kingdom. BA is one of the most effective psychotherapies available for depression and focuses on helping patients to increase their engagement with valued activities to help break out of the cycle of depression. Firstly, an archived anonymised dataset of routine depression measures from patients who have previously received the existing group BA treatment will be analysed. Secondly, the group BA treatment delivered to patients in 2017 will be enhanced with two treatment augmentations. One augmentation will target stasis outcomes through the addition of specific 'if-then' planning (known as implementation intentions) when setting between-session homework and the other augmentation will target patient drop-out by informing patients about group BA effectiveness and therapy-dose evidence. The stasis outcomes and drop-out rates from the enhanced treatment in the trial will be compared with the archived outcomes to see if the intervention has had an effect and the role of engaging in valued living as a mechanism of change for depression symptoms will be examined. It is hypothesised that a) 50% of patients who have received the existing BA group treatment for depression will have a stasis outcome, b) there will be a significant reduction in depression stasis outcomes and drop-out rate following the enhanced BA group treatment delivered in the trial and c) engagement in valued living will have a mediating effect on outcome for responding patients following the enhanced BA group treatment but the effect will not be present for patients with a stasis outcome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at below P25 for not_applicable depression

Timeline
Completed

Started Dec 2016

Shorter than P25 for not_applicable depression

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 11, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 21, 2016

Completed
10 days until next milestone

Study Start

First participant enrolled

December 1, 2016

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

May 4, 2018

Status Verified

May 1, 2018

Enrollment Period

1 year

First QC Date

November 11, 2016

Last Update Submit

May 1, 2018

Conditions

Keywords

Behavioural activationPsychotherapy, groupDepressionDepressive disorder

Outcome Measures

Primary Outcomes (1)

  • Change in Patient Health Questionnaire (PHQ-9) scores

    Validated 9-item self-report measure of depressive symptoms

    Week 1 (pre-treatment), at every weekly treatment session attended (for 8 weeks) and at week 8 (end of treatment)

Secondary Outcomes (4)

  • Patient attendance at treatment sessions

    Weeks 1-8 (every weekly treatment session - maximum of 8)

  • Change in Valued Living Questionnaire (VLQ) score

    Week 1 (pre-treatment), week 4 (at the 4th treatment session) and at week 8 (end of treatment)

  • Change in Generalised Anxiety Disorder Assessment (GAD-7) score

    Week 1 (pre-treatment), at every weekly treatment session attended (for 8 weeks) and at week 8 (end of treatment)

  • Change in Work and Social Adjustment Scale (WSAS) score

    Week 1 (pre-treatment), at every weekly treatment session attended (for 8 weeks) and at week 8 (end of treatment)

Other Outcomes (1)

  • Behavioural activation group (BAG) therapy adherence

    Weeks 1-8 (Every treatment session)

Study Arms (1)

Enhanced Behavioural Activation Groups

EXPERIMENTAL

Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations; 1. Implementation intentions 2. Dose-response psychoeducation

Behavioral: Behavioural Activation Group (BAG) Psychotherapy

Interventions

Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.

Enhanced Behavioural Activation Groups

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who access the Sheffield Improving Access to Psychological Therapies (IAPT) service (United Kingdom) with depression as the primary presenting problem
  • Patients with co-morbid anxiety symptoms can be included as long as depression is the primary diagnosis
  • Are referred to and choose the Behavioural Activation Group (BAG) treatment option
  • Able to attend the BAG intervention
  • Aged 18 or over

You may not qualify if:

  • Primary diagnosis that is not depression
  • Patients who do not choose BAG as a treatment option
  • Aged under 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sheffield Health and Social Care NHS Foundation Trust - Improving Access to Psychological Therapies Service

Sheffield, South Yorkshire, S3 7ND, United Kingdom

Location

Related Publications (1)

  • Gollwitzer, P. M. (1999). Implementation intentions: Strong effects of simple plans. American Psychologist, 54, 493-503.

    BACKGROUND

MeSH Terms

Conditions

DepressionDepressive Disorder

Interventions

Psychotherapy

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Behavioral Disciplines and Activities

Study Officials

  • Melanie K Simmonds-Buckley, BSc

    University of Sheffield

    PRINCIPAL INVESTIGATOR
  • Stephen Kellett, DClinPsy

    University of Sheffield & Sheffield Health and Social Care NHS Foundation Trust

    PRINCIPAL INVESTIGATOR
  • Glenn Waller, PhD

    University of Sheffield

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Research Student

Study Record Dates

First Submitted

November 11, 2016

First Posted

November 21, 2016

Study Start

December 1, 2016

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

May 4, 2018

Record last verified: 2018-05

Data Sharing

IPD Sharing
Will not share

The data will be anonymised and analysed collectively so individual participant data will not be identifiable within any reports or publications.

Locations